Questions List

What if an amyloidosis patient achieved CR from induction. Do you still offer ASCT?Posted onOctober 11, 2020 12:58 pm

Are there ngoing trials with anti-CD38 antibodies mono/ or combined with other drugs in WM? The CD38+ clone is not enough targeted by BTKs and for some patients exactly the IgM paraprotein ist of clinical significance and the PR with persistent paraprotein ist not suffecient response Posted onOctober 11, 2020 12:52 pm

Excelente Posted onOctober 11, 2020 12:49 pm

******** Session 9 ***********Posted onOctober 11, 2020 12:23 pm

It doesn't sound as if the current data collection procedures you are describing are all fully compliant with European data protection regulations? Posted onOctober 11, 2020 10:40 am

How is the pandemic affecting or will affect clinical trials?Posted onOctober 11, 2020 10:32 am

Question regarding iStopMM: are you also planning to perform sequencing studies on the MGUS bone marrow samples?Posted onOctober 11, 2020 10:00 am

******* Day 4 ********Posted onOctober 11, 2020 7:08 am

Do the panel think that we will still be using autologous CAR-T approaches in 5 years time?Posted onOctober 10, 2020 2:23 pm

.....Posted onOctober 10, 2020 1:39 pm

********** Session 7 **************Posted onOctober 10, 2020 1:32 pm

Congrats Posted onOctober 10, 2020 1:10 pm

Is the type of relapse ( as for example biochemical, clinical, extramedullary plasmacytoma) important in the treatment choice? Akrivi KostourouPosted onOctober 10, 2020 12:16 pm

What is the best strategy with venetoclax in case of a 11;14 patient? Is the earlier the better, or we should exhaust all the on label options first? Thanks G Varga, HungaryPosted onOctober 10, 2020 11:45 am

What is the best antibody combination (CD) currently used to define MRD by flowcytometry? Hayati MalaysiaPosted onOctober 10, 2020 11:17 am

The time now is 12:56 in ParisPosted onOctober 10, 2020 10:57 am

********** Adaptive **********Posted onOctober 10, 2020 10:43 am

Does the type of treatment used to achieve MRD negativity influence the duration of sustained MRD?Posted onOctober 10, 2020 9:57 am

Carlotta, do you think T cells in multiple myeloma bone marrow are neo-antigen-specific at all?Posted onOctober 10, 2020 9:54 am

What kind of genetic features or risk group stratification do you look at to select candidates for CAR-T treatment? (Ariene, Canada)Posted onOctober 10, 2020 8:22 am

Posted onOctober 10, 2020 8:18 am

The pts receiving Steroides because of Grad 2 ore more Col effects which was their follow up (responses; EFS OS)Posted onOctober 10, 2020 8:18 am

******* Day 3 ********Posted onOctober 10, 2020 6:27 am

What are the most potential combination antibody /CD used in MRD in flowcytometry?Posted onOctober 9, 2020 2:20 pm

Posted onOctober 9, 2020 2:14 pm

Is frailty reversible after initial treatment in elderly patient with Multiple Myeloma?Posted onOctober 9, 2020 1:36 pm

Posted onOctober 9, 2020 1:31 pm

testPosted onOctober 9, 2020 1:12 pm

Posted onOctober 9, 2020 12:50 pm

How to differentiate that the patients die because of treatment toxicity or due to aggressiveness of the clonal cells / relapse / refractory ? Especially in elder patients. Thanks. Hayati MalaysiaPosted onOctober 9, 2020 12:50 pm

In your opinion, is it possible a second treatment with CAR-T therapy after a delayed relapse occurs?Posted onOctober 9, 2020 12:16 pm

***** Day 2 *******Posted onOctober 9, 2020 10:27 am

Posted onOctober 9, 2020 8:48 am

Posted onOctober 9, 2020 8:28 am

**** Day 2 ***Posted onOctober 8, 2020 11:06 pm

Test 1Posted onOctober 8, 2020 6:45 pm

Test questionPosted onOctober 8, 2020 6:45 pm

Can sFLC immunoassays, Freelite, based on polyclonal antibody technology, and N Latex FLC, based on monoclonal antibodies be used interchangeably. Should we or not use these monoclonal antibodies for SFLC detection. Dr Ruchi, India Posted onOctober 8, 2020 3:02 pm

How often should we check the frailty in the elderly patient?Posted onOctober 8, 2020 2:53 pm

do we still need to use Bence Jones Proteinuria to follow up Myeloma or is it going to be replaced by Light Chains measurement ? B Namour NancyPosted onOctober 8, 2020 2:51 pm

Can we use the SFLC assay developed by Seimens for assessing SFLC ratio, as their kit uses monoclonal antibodies against the light chains, whereas the IMWG recommedns the use of polyspecific antisera for these kappa /lambda light chain. Dr Ruchi, Hematopathologist, India Posted onOctober 8, 2020 2:51 pm

which frailty score would you recommend for everyday clinicial practise? (H.Mian, Canada)Posted onOctober 8, 2020 2:41 pm

Dear Alessandra Larrocca, Odunukwe Nkiruka Nnonyelum et al in 2015 found that 57% of patients studied In Nigeria were below the age of 60 years. This is a common finding in other studies too. As a hematologist, I have seen similar trends too. What do you think is the reason younger people are diagnosed with MM in Nigeria as against the elderly in your Center? Thank you. Dr. Angela Ugwu Consultant Hematologist NigeriaPosted onOctober 8, 2020 2:37 pm

If we had limited resources, which cytogenetic abnormalities would you suggest we test at minimum? Would you suggest testing the same panel at each relapse? (Hira Mian, Canada)Posted onOctober 8, 2020 2:28 pm

To Shaji Kumar, MGRS is a term I heard in your presentation. Kindly throw more light on this. Dr Angela Ugwu from NigeriaPosted onOctober 8, 2020 2:12 pm

Would you treat a patient just on the basis of a single sFLC ratio >100?Posted onOctober 8, 2020 2:04 pm

Avet-Loiseau: Do we have to ask for sFLC measurement in case of IgG or IgA myeloma? 2nd question: we have now several tests for sFLC. Are they equivalent? Posted onOctober 8, 2020 1:59 pm

How effective is Minimal Residual Disease (MRD) to define multiple myeloma at different stages (MGUS, SMM & MM) comparing to current diagnostic testing? Hayati Malaysia Posted onOctober 8, 2020 1:26 pm

While sorting abnormal PCs, we realize that some of the PC express CD56 and some lose CD19 and still polyclonal. Do you sort plasma cells after a combined staining with surface antigens combine with light chains. Does the cytoplasmic staining influence molecular and FISH workup after sorting such cells. Ritu Gupta (India) Posted onOctober 8, 2020 1:17 pm

Ritu Gupta-India Posted onOctober 8, 2020 1:12 pm

Oligosecretory and non secretory myeloma have been classified based on certain criteria. What is your take on these entites with respect to SMM and how does one recognize the NS-SMM and OS-SMM. Posted onOctober 8, 2020 1:11 pm

Why is it raining in Berlin? Posted onOctober 8, 2020 1:10 pm

Zeev test excellent presentation Posted onOctober 8, 2020 12:56 pm

QuestionPosted onOctober 8, 2020 12:40 pm

testsssPosted onOctober 8, 2020 11:45 am

testPosted onOctober 8, 2020 10:59 am

Hello therePosted onOctober 8, 2020 10:39 am

aslkjd alskjd alskjd a lksjs lkjaslk jslk j aslkjd alskjd alskjd a lksjs lkjaslk jslk j aslkjd alskjd alskjd a lksjs lkjaslk jslk jaslkjd alskjd alskjd a lksjs lkjaslk jslk jaslkjd alskjd alskjd a lksjs lkjaslk jslk jaslkjd alskjd alskjd a lksjs lkjaslk jslk jaslkjd alskjd alskjd a lksjs lkjaslk jslk jaslkjd alskjd alskjd a lksjs lkjaslk jslk jaslkjd alskjd alskjd a lksjs lkjaslk jslk jPosted onOctober 8, 2020 9:57 am

Test questionPosted onOctober 8, 2020 9:56 am